Clinical trials: Diabetic Retinal Disease
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration
- Trial name
- NCT06305416
- Testing
- Ranibizumab 10mg/ml Injection, Lucentis
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Incepta Pharmaceuticals Ltd
Diabetic Retinopathy, Diabetic Macular Edema
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
The purpose of this study is to determine the effect of enhancements to the myVisionTrack® in regards to patient compliance and test-retest variability.
- Trial name
- DRAMA (NCT01728883)
- Testing
- Home vision monitoring using myVisionTrack®
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vital Art and Science Incorporated
Proliferative Diabetic Retinopathy
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
- Trial name
- NCT02753400
- Testing
- emixustat hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Kubota Vision Inc.
Diabetic Macular Edema
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy
- Trial name
- NCT00665106
- Testing
- NOVA63035 "Corticosteroid"
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen SAS
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Macular Edema
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
The objectives of this study are to investigate the safety and effectiveness of EYLEA
- Trial name
- NCT02425501
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 646 people
- Sponsor
- Bayer
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4…
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT06664502
- Testing
- EYE201
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- EyeBiotech Ltd.
Diabetes Mellitus, Diabetic Macular Edema
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the…
- Trial name
- VIDI (NCT02302079)
- Testing
- ASP8232, ranibizumab
- Where
- 21 sites in United States
- Volunteers
- 96 people
- Sponsor
- Astellas Pharma Europe B.V.
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Diabetic Retinopathy
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
This study is open to adults with diabetic macular ischemia who have received laser treatment. The main purpose of this study is to find out whether people with diabetic macular ischemia can tolerate a medicine called BI 765128.
- Trial name
- PARTRIDGE (NCT04919499)
- Testing
- BI 765128
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Epiretinal Membrane, Macular Hole
UNITY VCS Vitreoretinal Surgery
This purpose of this study is to compare the safety and effectiveness of two eye surgery systems-UNITY VCS and CONSTELLATION-in treating adults with vitreoretinal diseases or disorders.
- Conditions
- Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction
- Trial name
- NCT07054281
- Testing
- UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
- Where
- 8 sites in United States
- Sponsor
- Alcon Research
Diabetic Macular Edema, Diabetic Retinopathy
4D-150 in Patients With Diabetic Macular Edema
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
- Trial name
- NCT05930561
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- 4D Molecular Therapeutics
Diabetes Mellitus, Type 2
Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects
The purpose of this study is to investigate microvascular endothelial function in the retina of lean, obese, and type 2 diabetic subjects and to compare microvascular endothelial function in the retina with several other…
- Trial name
- NCT01241370
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ELAB-Logistics
AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP)
Retinal Investigation Using Optos OCT Device
Retinal investigation using OCT with control and diseased eyes
- Conditions
- AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP), Diabetic Retinopathy, Control Patients
- Trial name
- NCT06846151
- Testing
- retinal functional imaging
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Diabetic Retinopathy
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
The purpose of this study is to determine whether supplementation with OcuStem, a nutritional supplement, will reduce the progression of mild to moderate diabetic retinopathy.
- Trial name
- NCT02353923
- Testing
- OcuStem Supplementation
- Volunteers
- 30 people
- Sponsor
- Aidan Products LLC